Rousselet Morgane, Feuillet Fanny, Gerardin Marie, Jolliet Pascale, Hardouin Jean-Benoit, Victorri-Vigneau Caroline
a Centre for Evaluation and Information on Pharmacodependence - Addictovigilance , Clinical Pharmacology Department, University Hospital , Nantes , France.
b INSERM U1246 SPHERE "methods in Patient-centered outcomes and Health Research" , Nantes University , Nantes , France.
Expert Opin Drug Saf. 2017 Sep;16(9):1063-1069. doi: 10.1080/14740338.2017.1346084. Epub 2017 Jun 28.
In France, an addictovigilance network is responsible for evaluating drug dependence, by drawing on pharmacoepidemiological studies, clinical studies and by assessing healthcare professionals' reports on problematic consumption.
The aim of this study was to determine whether zolpidem and zopiclone have different dependence profiles, based on healthcare professionals' reports, and to identify various consumer dependence profiles among zolpidem users and among zopiclone users. Dependence in reports was assessed using the EGAP scale; a scale developed using the DSM diagnostic dependence criteria.
The comparison of dependence profiles for zolpidem and zopiclone showed differences both in total EGAP score and EGAP item positivity. The descriptive analysis showed that EGAP scores were higher for zolpidem than for zopiclone, suggesting more severe problematic consumption with zolpidem. For zolpidem 2 subpopulations of consumers were identified, with one subpopulation's consumption being more severe than the other, with a significantly higher total EGAP score and more harmful consequences. No subpopulation was highlighted for zopiclone.
These results were in favour of a higher prevalence of physical and compulsive signs of dependence and of harmful consequences of dependence, with zolpidem than with zopiclone.
在法国，一个药物成瘾监测网络负责通过药物流行病学研究、临床研究以及评估医疗保健专业人员关于问题性药物使用的报告来评估药物依赖性。
本研究的目的是根据医疗保健专业人员的报告，确定唑吡坦和佐匹克隆是否具有不同的依赖性特征，并识别唑吡坦使用者和佐匹克隆使用者中的各种消费者依赖性特征。报告中的依赖性使用EGAP量表进行评估；该量表是使用DSM诊断依赖性标准制定的。
唑吡坦和佐匹克隆依赖性特征的比较显示，EGAP总分和EGAP项目阳性率均存在差异。描述性分析表明，唑吡坦的EGAP评分高于佐匹克隆，表明唑吡坦的问题性药物使用更严重。对于唑吡坦，识别出了2个消费者亚群，其中一个亚群的药物使用比另一个更严重，其EGAP总分显著更高，且有害后果更多。佐匹克隆未突出显示亚群。
这些结果表明，与佐匹克隆相比，唑吡坦出现身体和强迫性依赖迹象以及依赖有害后果的发生率更高。
